12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Ariad sales and marketing update

Ariad disclosed in its 2Q13 earnings that it launched Iclusig ponatinib in Germany, U.K. and Austria to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). In a conference...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >